 X4 Pharmaceuticals Inc NASDAQ: XFOR shares are trading lower despite releasing what it described as positive phase 2 data for mavorixafor for WHIM syndrome, a rare congenital immune deficiency. In a poster presentation at the American Society of Hematology Annual Meeting, treatment with mavorixafor led to increases in neutrophils, lymphocytes, and monocytes and sustained improvements in infections and warts ongoing Phase 2 open-label extension trial. 